Brief: EMA'S CHMP Says No Need for Separate Mounjaro Indication for OSA in Obese Adults

Geron

13/12/2024 11:48

Dec 13 (Reuters) - EMA'S CHMP: 
    * EMA'S CHMP: FINALISED ASSESSMENT OF APPLICATION TO EXTEND
USE OF
MOUNJARO TO INCLUDE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA IN
ADULTS WITH OBESITY
    * EMA'S CHMP:  SEPARATE INDICATION FOR TREATMENT OF MODERATE
TO
SEVERE OSA IN ADULTS WITH OBESITY IS NOT NEEDED FOR MOUNJARO
    * EMA'S CHMP: ADOPTED POSITIVE OPINION FOR BEYONTTRA
(ACORAMIDIS)
    * EMA'S CHMP: KAVIGALE (SIPAVIBART) RECEIVED POSITIVE
OPINION
    * EMA'S CHMP: RYTELO GETS POSITIVE OPINION FOR TREATMENT OF
ADULTS
WITH TRANSFUSION-DEPENDENT ANAEMIA
    * EMA'S CHMP: RECOMMENDED GRANTING CONDITIONAL MARKETING
AUTHORISATION FOR WELIREG (BELZUTIFAN)

Source text:  ID: 
Further company coverage:  LLY.N 

 ((Reuters.Briefs@thomsonreuters.com))